

SNS COLLEGE OF ALLIED HEALTH SCIENCES



SNS Kalvi Nagar, Coimbatore - 35 Affiliated to Dr MGR Medical University, Chennai

DEPARTMENT : CARDIO PULMONARY PERFUSION CARE TECHNOLOGY

COURSE NAME: PHARMACOLOGY

UNIT: DRUGS AFFECTING RESPIRATORY SYSTEM

TOPICS: BRONCHODILATORS, INHALED CORTICOSTEROIDS, COMBINATION INHALERS, LEUKOTRIENE MODIFIERS, MAST CELL STABILIZERS, PHOSPHODIESTERASE - 4 INHIBITORS, MONOCLONAL ANTIBODIES



DRUGS AFFECTING RESPIRATORY SYSTEM



BRONCHODILATORS

Beta2-Adrenergic Agonists:

Short-acting (SABA):

Albuterol, Levalbuterol:

Mechanism: Activate beta2 receptors, leading to bronchodilation.

Indications: Acute bronchospasm in asthma and COPD.





Long-acting (LABA):

Formoterol, Salmeterol, Vilanterol:

Mechanism: Prolonged bronchodilation for maintenance therapy.

Indications: Maintenance treatment of asthma and COPD.





Anticholinergic Bronchodilators:

Ipratropium, Tiotropium, Umeclidinium:

Mechanism: Block muscarinic receptors, causing bronchodilation.

Indications: COPD, sometimes used in asthma.



INHALED CORTICOSTEROIDS (ICS)



Fluticasone, Budesonide, Beclomethasone:

Mechanism: Reduce airway inflammation and suppress immune response.

Indications: Asthma and COPD, particularly for antiinflammatory maintenance therapy.



LEUKOTRIENE MODIFIERS



Montelukast, Zafirlukast, Zileuton:

Mechanism: Inhibit leukotriene synthesis or block receptors, reducing inflammation.

Indications: Asthma and, to some extent, allergic rhinitis.



COMBINATION INHALERS



Fluticasone/Salmeterol, Fluticasone/Vilanterol:

Budesonide/Formoterol,

Mechanism: Combine corticosteroid and long-acting beta2-agonist for both anti-inflammatory and bronchodilator effects.

Indications: Asthma and COPD.



MAST CELL STABILIZERS



Cromolyn, Nedocromil:

Mechanism: Inhibit mast cell degranulation, reducing release of inflammatory mediators.

Indications: Prophylaxis in asthma and allergic rhinitis.



PHOSPHODIESTERASE - 4 (PDE-4) INHIBITORS



Roflumilast:

Mechanism: Inhibits PDE-4, reducing inflammation.

Indications: Severe COPD with chronic bronchitis.



MONOCLONAL ANTIBODIES



Anti-IgE Antibodies:

Omalizumab:

Mechanism: Binds to circulating IgE, reducing its availability.

Indications: Severe allergic asthma.





Anti-IL-5 Antibodies:

Mepolizumab, Reslizumab, Benralizumab:

Mechanism: Target eosinophils, reducing inflammation.

Indications: Severe eosinophilic asthma.



TECHNICIAN ROLE



Regular assessment of lung function and symptoms.



ASSESSMENT



- What is Bronchodilators?
- What is Monoclonal Antibodies?